for those selling, I think you'll regret itthe news came on a Friday just before the end of summer. not many institutional or big investors are gonna jump on this this afternoon. let the news get out to the big players (next week is the last week of summer so that might not be a good indication either) and then see what happens. With a market cap still under $200m cdn (which is about $150m USD) this is dirt cheap compared to what US biotechs in similiar stages are trading at.
Now that the stock has been further derisked, there will be a lot more big players wanting to get shares. As well, we now have an open door for a partnership agreement to be announced!